[106例采用标准CHOP方案治疗的外周T细胞淋巴瘤患者的临床结局]

[Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen].

作者信息

Huang Hui-Qiang, Peng Yu-Long, Lin Xu-Bin, Sun Xiao-Fei, Lin Tong-Yu, Xia Zhong-Jun, Li Yu-Hong, Cai Qing-Qing, He You-Jian, Jiang Wen-Qi, Guan Zhong-Zhen

机构信息

Department of Medical Oncology, Cancer Center, Sun Yat-sen university, Guangzhou, Guangdong, 510060, P.R.China.

出版信息

Ai Zheng. 2004 Nov;23(11 Suppl):1443-7.

PMID:15566653

Abstract

BACKGROUND & OBJECTIVE: T-cell Non-Hodgkin's lymphoma (NHL) are common in Asia, It's biological behavior is different from B-cell NHL. It often shows lower chemo-sensitivity, high incidence of relapse and poor prognosis. This study was designed to analyse the clinical characteristics and to evaluate the effectiveness and toxicity of standard CHOP regimen in the treatment of peripheral T-cell lymphomas-unspecified (PTCL-U) according to the Revised European- American Lymphoma (REAL) classification.

METHODS

106 patients with PTCL-U were treated by standard CHOP regimen with or without involved field radiotherapy from January 1997 to December 2003 in Cancer Center, Sun Yat-sen University, The clinical characteristics, response and long-term survival rates were analysed, retrospectively.

RESULTS

Early stages (I-II) were present in 78.3% (83/106) of the patients. Extranodal involvement account for 84.0% (89/106) with 34.9% (37/106) of more than 1 involved extranodal sites. The percentage of IPI score 0-1 was 78.3% (83/106). All the patients were treated by standard CHOP regimen plus IFRT for bulky disease. 55.7% (59/106) patients were treated by chemotherapy alone and 43.3% (46/106) were treated by chemotherapy plus radiotherapy. The overall response rate was 81.0% (85/105) with 58.2%(65/105) complete remission (CR) rates. The response rate of chemotherapy alone were 69.5% (41/59) and CR rates was 44.1% (26/59). The median duration of response was 16 months (1-88 months). The actual 1, 3 and 5 year overall survival rates were 69.9%, 42.9% and 22.0%, respectively. Median survival times were 24 (12-36) months.

CONCLUSION

Long-term survival of PTCL-U treated by standard CHOP regimen were poor. Further investigation is wanted.

摘要

背景与目的

T细胞非霍奇金淋巴瘤（NHL）在亚洲较为常见，其生物学行为与B细胞NHL不同。它常表现出化疗敏感性较低、复发率高及预后较差。本研究旨在根据修订的欧美淋巴瘤（REAL）分类分析外周T细胞淋巴瘤未特定型（PTCL-U）的临床特征，并评估标准CHOP方案治疗PTCL-U的有效性和毒性。

方法

1997年1月至2003年12月，中山大学肿瘤防治中心对106例PTCL-U患者采用标准CHOP方案治疗，部分患者联合受累野放疗，回顾性分析其临床特征、疗效及长期生存率。

结果

78.3%（83/106）的患者为早期（I-II期）。结外受累占84.0%（89/106），其中34.9%（37/106）有1个以上结外受累部位。国际预后指数（IPI）评分0-1分的患者占78.3%（83/106）。所有患者均采用标准CHOP方案加针对大肿块病变的受累野放疗。55.7%（59/106）的患者仅接受化疗，43.3%（46/106）的患者接受化疗加放疗。总缓解率为81.0%（85/105），完全缓解（CR）率为58.2%（65/105）。单纯化疗的缓解率为69.5%（41/59），CR率为44.1%（26/59）。中位缓解持续时间为16个月（1-88个月）。实际1年、3年和5年总生存率分别为69.9%、42.9%和22.0%。中位生存时间为24（12-36）个月。